Prelude Therapeutics Inc Annual Operating Income (Loss) in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Prelude Therapeutics Inc quarterly/annual Operating Income (Loss) history and growth rate from 2019 to 2023.
  • Prelude Therapeutics Inc Operating Income (Loss) for the quarter ending September 30, 2024 was -$34.4M, a 2.97% decline year-over-year.
  • Prelude Therapeutics Inc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$143M, a 11.7% decline year-over-year.
  • Prelude Therapeutics Inc annual Operating Income (Loss) for 2023 was -$132M, a 7.07% decline from 2022.
  • Prelude Therapeutics Inc annual Operating Income (Loss) for 2022 was -$124M, a 8.62% decline from 2021.
  • Prelude Therapeutics Inc annual Operating Income (Loss) for 2021 was -$114M, a 93.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$132M -$8.74M -7.07% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-15
2022 -$124M -$9.81M -8.62% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-15
2021 -$114M -$55M -93.5% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 -$58.8M -$30.7M -109% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-17
2019 -$28.1M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.